Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Cryoport, Inc. on July 16, 2014, with the earliest event reported on that same date. The filing details a private placement of securities and the execution of indemnification agreements with directors and executive officers.
Key Financial Metrics and Transaction Details
- Capital Raised: The company entered into definitive agreements for a private placement generating aggregate gross proceeds of $303,600.
- Net Proceeds: Estimated net proceeds are approximately $264,132 after cash offering expenses.
- Use of Proceeds: Net proceeds are intended for working capital purposes.
- Securities Issued: 26,300 Units were issued at $12.00 per Unit. Each Unit consists of one share of Class A Convertible Preferred Stock and one warrant to purchase eight shares of Common Stock.
- Warrant Terms: Warrants are immediately exercisable at $0.50 per share and expire on March 31, 2019.
- Placement Agent Fees: Emergent Financial Group, Inc. received a 10% commission, a 3% non-accountable finance fee, and reimbursement of legal expenses up to $40,000. They also received warrants to purchase three shares of Common Stock per Unit issued.
- Prior Transaction: A previous placement on June 30, 2014, raised $51,000 gross proceeds (approx. $44,370 net) for 4,250 Units.
Material Changes and Recent Activity
The primary material change is the entry into definitive agreements for the private placement described above. Additionally, on July 18, 2014, the company entered into indemnification agreements with six directors and executive officers, providing protection beyond Nevada Revised Statutes for actions taken in good faith.
Outlook, Risks, and Unusual Items
The offering of Units to new investors is extended through August 15, 2014. The sale of securities was conducted under exemptions provided by Rule 506 of Regulation D and/or Section 4(2) of the Securities Act of 1933. The filing does not provide specific revenue, profit, or debt metrics for the reporting period, as this is a transactional report rather than a periodic financial statement.
Investor Verification Checklist
- Verify the total dilution impact of the 26,300 Units issued, including the 8:1 warrant ratio.
- Confirm the actual cash offering expenses deducted from the $303,600 gross proceeds to validate the net amount available for working capital.
- Review the full text of the Subscription Agreements (Exhibits 10.34 and 10.35 referenced in the filing) for specific conversion terms of the Preferred Stock.
- Assess the financial impact of the placement agent fees (13% total of gross proceeds plus legal reimbursement) on the company's cash position.